Thursday, December 10, 2020

Safety and feasibility of upper limb cardiopulmonary exercise test in Friedreich ataxia

›
Chiara Pane, Andrea Salzano, Assunta Trinchillo, Claudia Del Prete, Carlo Casali, Christian Marcotulli, Giovanni Defazio, Vincenzo Guardasol...
Tuesday, December 8, 2020

Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update

›
BALA CYNWYD, Pa., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology co...

Molecular Defects in Friedreich’s Ataxia: Convergence of Oxidative Stress and Cytoskeletal Abnormalities

›
Frances M. Smith and Daniel J. Kosman; Front. Mol. Biosci., doi:10.3389/fmolb.2020.569293 This review serves to outline a brief history of ...

Targeting Expanded Repeats by Small Molecules in Repeat Expansion Disorders

›
Nakamori, M. and Mochizuki, H. (2020), Mov Disord. doi:10.1002/mds.28397   Recent technological advancements in genetic analysis have allowe...
Saturday, December 5, 2020

Coronary Artery Disease in Patients With Friedreich's Ataxia

›
ClinicalTrials.gov Identifier: NCT04649866. Vasculopathy and Remodeling of Coronary Arteries in FRDA Patients. Patients with HCM can then d...
Thursday, December 3, 2020

Afrontamiento familiar ante el diagnóstico y evolución de la enfermedad ataxia de Friedreich, «Family dealing with the diagnosis and evolution of Friedreich’s ataxia disease»

›
Erika E. López Rios, Yeisy C., Guarate Coronado; Ocronos. Vol. III. Nº 8– Diciembre 2020. Pág. Inicial: Vol. III; nº8:12;  ORCID iD:  http:/...

Ferroptosis: molecular mechanisms and health implications

›
Daolin Tang, Xin Chen, Rui Kang, Guido Kroemer; Cell Res (2020). doi:10.1038/s41422-020-00441-1 The ferroptosis inhibitor SRS11-92 is highly...

Altered Expression of Mitoferrin and Frataxin, Larger Labile Iron Pool and Greater Mitochondrial DNA Damage in the Skeletal Muscle of Older Adults

›
Picca, A.; Saini, S.K.; Mankowski, R.T.; Kamenov, G.; Anton, S.D.; Manini, T.M.; Buford, T.W.; Wohlgemuth, S.E.; Xiao, R.; Calvani, R.; Coel...
Monday, November 30, 2020

PTC Therapeutics Announces Initiation of Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia

›
SOUTH PLAINFIELD, N.J., Nov. 30, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of the registrat...
Saturday, November 28, 2020

FDA sends Reata back to the drawing board

›
Evaluate Vantage, Madeleine Armstrong, November 25, 2020 The need for another pivotal trial of omaveloxolone in Friedreich's ataxia look...